Biophan's Nanotechnology Portfolio Expands
Friday January 9, 7:54 am ET
US Patent Granted Which Provides Biophan Additional Nanotechnology Rights

ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 9, 2004--Biophan Technologies, Inc. (OTC BB: BIPH), an innovator, developer, and marketer of advanced biomedical technology, today announced that its licensor for nanomagnetic particle technologies has been issued a U.S. patent, which covers the use of nanomagnetic particle technology on medical devices including catheters, guidewires, and endoscopes, and other medical devices. The patent was issued to Nanoset, LLC, which has provided Biophan with the worldwide exclusive medical rights to the technology.
The nanotechnology patents are a subset of over 50 pending patents filed by Nanoset and Biophan and are a core driver of Biophan's strategic plan of creating and maintaining a dominant position in this important new growth area. Biophan and Nanoset have had additional patents allowed by the U.S. patent office and will announce these as they are issued. The patent can be viewed at www.biophan.com/patents/3.html.

"Working with Nanoset, we have filed nine additional patent applications in this important area of nanotechnology, all focused on approving MRI imaging and safety for biomedical devices," noted Michael Weiner, Biophan's chief executive officer. "The newly issued patent includes 43 claims for sheaths and encapsulations which provide improved MRI safety and imaging quality, with minimal impact on existing manufacturing processes."

Mr. Weiner concluded, "This is the second U.S. patent issued to Nanoset, and expands the application of novel nanomagnetic shielding technology to surgical tools that today cannot effectively be used in a Magnetic Resonance Imaging (MRI) environment."

About Nanoset, LLC

Nanoset, LLC, based in East Rochester, NY, develops nanomagnetic particle coatings. Nanoset's research and development has been conducted with Alfred University, a world leader in ceramics and thin-film coatings. Nanoset and Biophan are jointly developing technologies for the medical device industry.

About Biophan Technologies, Inc.

Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed 51 related patents that will help establish Biophan products as the standard of care in each of their markets. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

--------------------------------------------------------------------------------
Contact:
Trilogy Capital Partners, Inc.
Investor Relations:
Racquel Rivera, 800-330-6540
racquel@trilogy-capital.com
or
Press Interviews:
Biophan Technologies, Inc.
Michael Weiner, 585-214-2441

--------------------------------------------------------------------------------
Source: Biophan Technologies, Inc.

Biophan CEO to Present Today at the 2004 Medical Device Forum
Thursday January 15, 10:37 am ET
Presentation Includes Observations on Biomedical Device Future

ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 15, 2004--Biophan Technologies, Inc. (OTC BB: BIPH), an innovator, developer and marketer of advanced biomedical technology, announced that Michael Weiner, president and chief executive officer of Biophan, will present today at the 2004 Leadership Forum on Medical Devices taking place in New York City. The forum will offer a broad overview of the international medical device industry as well as in-depth analysis of some of the upcoming new technologies in this field.
In addition to Mr. Weiner, announced speakers include Mr. Tomas Puusepp, President & CEO Elekta, Inc., Mr. Michael J. Neuberger, Managing Director, Investment Banking, SG Cowen Securities Corporation and Mr. Bengt Modeer, Vice President, Corporate Communications, Gambro AB.

Mr. Weiner's presentation, which will be posted in its entirety on the company's website, at 4pm Eastern today, www.biophan.com, includes the following remarks:

"...we see the following things on the overall biomedical device horizon:

dramatic improvements in biocompatibility of devices...
miniaturization of devices...
improvements in implantable power systems...
Nanomagnetic materials will allow devices such as neurostimulators, which today have to be replaced every two to three years, to potentially last for the life of the patient...
Smart stents, and smart shunts, offering expanded capabilities...
The use of fiber-optics in the body...
Nanomagnetic particle contrast agents yielding advances in MRI imaging.
We expect that, in time, we will see implanted miniature lasers for diagnostics and therapeutics.
Devices which can detect specific cell types and kill or harvest them...
Devices which can restore full cardiac output to a diseased or failed heart...
Mr. Weiner concludes his presentation by noting, "We are pleased to report that we are making contributions, wherever possible, on this exciting forward horizon, to ensure these devices are all designed to not only achieve these miracles as described, but where needed, to design in MRI safety and compatibility. We see a bright future, indeed, for human beings, for the biomedical device, industry, and for Biophan."

About Biophan Technologies, Inc.

Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment and other sources of powerful magnetism or radio frequency signals. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed over 50 related patent applications that will help establish Biophan products as the standard of care in each of their markets.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

--------------------------------------------------------------------------------
Contact:
Trilogy Capital Partners, Inc.
Racquel Rivera, 800-330-6540
racquel@trilogy-capital.com
or
Press Interviews:
Michael Weiner, 585-214-2441

--------------------------------------------------------------------------------
Source: Biophan Technologies, Inc.

THIS CAME OUT OFTER THE BELL FRIDAY.........

Biophan Expands Rights with Nanotechnology Partner
Friday January 16, 5:54 pm ET

ROCHESTER, N.Y.--(BUSINESS WIRE)--Jan. 16, 2004--Biophan Technologies, Inc. (OTC BB: BIPH), an innovator, developer and marketer of advanced biomedical technology, today announced it has secured additional technology rights expanding its exclusive license for use of nanomagnetic particle and other technology. Michael Weiner, chief executive officer of Biophan, made the announcement.
The technology rights are granted under an expanded license agreement executed on January 15, 2004 with Nanoset, LLC that increases Biophan's rights to technology that may be applied to medical devices and other uses. The expanded rights include the exclusive right to any technology that affects magnetic resonance imaging (MRI) safety or image compatibility or involves an implantable power system.

Under the license agreement, Biophan currently has rights to two United States patents and twelve pending United States patent applications. In addition Nanoset has received an indication from the United States Patent Office of allowablity for many of the claims of a patent application that relates to the Nanoview technology previously announced.

"It should be clear that Biophan is continuing to successfully implement its strategic plan of creating a very substantial and diversified biomedical portfolio," stated Mr. Weiner. "With these additional rights, we believe management and the board of directors have demonstrated our commitment to capitalize on these exciting nanotechnology and other technology markets."

Mr. Weiner concluded by noting, "With the proceeds from our recent financing, Biophan is well fortified to compete in these fast moving markets. We are well positioned to exploit our current technology and acquire complementary technology."

About Nanoset, LLC

Nanoset, LLC, based in East Rochester, NY, develops nanomagnetic particle coatings. Nanoset's research and development has been conducted with Alfred University, a world leader in ceramics and thin-film coatings. Nanoset and Biophan are jointly developing technologies for the medical device industry.

About Biophan Technologies, Inc.

Biophan Technologies develops and markets cutting-edge technologies used to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tool--safe and compatible with magnetic resonance imaging (MRI) equipment and other sources of powerful magnetism or radio frequency signals. Committed to growth through innovation and developmental leadership, Biophan's management holds exclusive licenses for four issued U.S. patents and has filed 51 related patents that will help establish Biophan products as the standard of care in each of their markets. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

--------------------------------------------------------------------------------
Contact:
Investor Relations Contact:
Trilogy Capital Partners, Inc.
Racquel Rivera, 800-330-6540
racquel@trilogy-capital.com
or
Press Interviews:
Michael Weiner, 585-214-2441

--------------------------------------------------------------------------------
Source: Biophan Technologies, Inc.

BIPH - BIOPHAN TECHGS (OTCBB)
Date Open High Low Last Change Volume % Change
01/16/04 1.18 1.27 1.01 1.18 -0.02 6216200 -1.67%

Composite Indicator
Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 3775225

Medium Term Indicators
40 Day Commodity Channel Index Hold
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 75% - Buy
50-Day Average Volume - 2347068

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 1409445

Overall Average: 88% - Buy

Price Support Pivot Point Resistance

1.18 0.89 1.15 1.41

I THINK THIS IS A VERY STRONG PLAY THIS WEEK.

Currently, I am projecting BIPH to fall below
1.00 per share before Friday close. My hunch
is BIPH will fall to .75 to .80 within ten
to twenty days. This type of fall should be
observable with all nanotech stocks.

I would not be suprised to see BIPH around
.30 to .40 per share in thirty to sixty days.

A number of problems here. BIPH is clearly a
research and development company reporting
zero revenues and high losses for its history,
with an exception of small revenue earnings
this past quarter. I have not researched yet
to discover if this revenue earning is not
true revenue but rather creative book cooking,
such as claiming payment of a loan as a net
gross profit, which is common but unethical.

Another problem is BIPH stock prices are
artificially inflated by fifty to sixty
percent resulting from a bandwagon effect.
Investors are buying BIPH simply because
most believe "nanotech" stocks are hot.
Many investors have already lost significant
amounts of money, investing in BIPH. This
is true for virtually all nanotech stocks.

Consider Mad Cow stocks and Bush "Moon"
stocks and their recent histories. Millions
of dollars are lost on those because people
jumped on a bandwagon and were taken for
a ride, an unpleasant ride.

Yet another problem is nanotech stocks are
due for a major shake-down. Only those in
the best financial conditional with the
best market connections, will survive well.

Could be I am completely wrong on this. Some
bandwagon stocks are known to skyrocket when
you least expect. These new online investors
add an unpredictable factor to our markets.

Never buy, sell nor hold based on my opinion.
I could be wrong. You could lose money or not
make as much money, based on my opinions. Do
good research and make prudent decisions.

Purl Gurl

trading in europe light but going up

BIPH going to gap way up B/A = @+.12